Aspirin Responsiveness in Women at Risk for Cardiac Events
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The objective of this pilot study is to evaluate the prevalence of biological aspirin
resistance in women at risk for CHD taking low dose (81 mg) aspirin. Aspirin responsiveness
will be measured with the VerifyNow device (Accumetrics; San Diego, CA). Those women
identified as biologically resistant will be switched to aspirin 325 mg for 14 days and then
re-tested for aspirin responsiveness.